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ABSTRACT 
 
Current methods for detecting metallothionein (MT) protein expression lack the 
specificity to distinguish between all twelve human isoforms.  Each, however, can be 
distinguished by the masses of their acetylated, cysteine-rich, hydrophilic N-terminal 
tryptic peptides.  These properties were exploited to develop a mass spectrometry-
based method for their simultaneous quantification.   
Human kidney HK-2 epithelial cells expressing recombinant MT-3 were grown in 
the presence or absence of cadmium.  Cytosolic proteins were alkylated with 14N- or 
15N-iodoacetamide and digested with trypsin.  The N-terminal MT peptides were 
enriched by two-dimensional liquid chromatography and analyzed by MALDI-TOF/TOF 
mass spectrometry.  Relative expression was measured by combining 14N-labeled 
control and 15N-labeled cadmium-treated cytosols before trypsin digestion and 
determining monoisotopic peak ratios of the targeted peptides.  Absolute quantification 
was accomplished with 15N-labeled synthetic peptides.   
Seven isoforms (MT-1E, MT-1F, MT-1G2, MT-1M, MT-1X, MT-2, and MT-3) were 
detected and quantified.  The dynamic range was sufficient to detect 67-fold differences 
in abundance and 12-fold induction for some isoforms.  Combined, MTs represented 
0.3% to 1.5% of total cytosolic protein.  The mRNA isoform expression levels differed in 
both the rank order and fold induction. 
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The assay was also applied to four malignant (MCF-7, Hs578T, T-47D, and MDA-
MB-231) and one non-malignant (MCF-10A) human breast cell lines.  The malignant cell 
lines were either estrogen receptor positive (ER+) or estrogen receptor negative (ER-).  
Three MT isoforms (MT-2, MT-1E, and MT-1X) were quantified in the breast cells.  In 
regards to the ER status of the cells, the ER+ malignant cells had low MT protein levels 
while the ER- malignant cells had a significant overexpression of MTs compared to the 
control.  When comparing the ER+ to ER- cells, there was between a 5.5 – 14.5 fold 
increase in protein expression of the individual MT isoforms or a 38-fold difference in 
abundance between all MT isoforms.  This method expands the usefulness of human MT 
isoforms as potential biomarkers for specific diseases or environmental exposures to 
heavy metals. 
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CHAPTER I 
INTRODUCTION 
Background of Metallothioneins 
Metallothioneins (MTs) were first identified in equine kidney by Margoshes and 
Vallee in 19571 and are a family of small, highly conserved proteins with the specific 
capacity to bind metal ions2-4.  The mammalian MTs are typically 61- to 68-amino acid 
proteins possessing a large number of highly catalytic cysteine residues.  These cysteine 
residues are strictly conserved among species with arrangement in motifs that form two 
distinct metal-binding domains linked by a short peptide.  There are several biological 
roles that the MTs are proposed to have in cellular homeostasis.  The first is derived 
from their exceptional metal binding capacity and as such they contribute to the 
homeostasis of metal ions within the cell.  Due to the fact that high concentrations of 
both essential and non-essential metal ions, like zinc, cadmium, mercury and lead can 
be toxic, the MTs are also involved in protection of the cell from acute heavy metal 
toxicity2-4.  The MTs also can function in zinc metabolism by regulating the activity of 
fast-exchanging metalloproteins, such as the zinc finger-containing protein Sp1 and the 
tumor suppressor gene, p535-8.  The MTs are also looked upon as stress proteins 
participating in a variety of protective functions since they are also induced by many 
stimuli other than metals, such as hormones and cytokines.  Because the MTs are 
capable of scavenging free radicals they can play a role in the protection of cells and 
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tissues against oxidative injury associated with such insults as radiation, lipid 
peroxidation, and inflammation. 
The MT Gene Cluster 
The study of the role that alterations in metallothionein expression may have in 
human disease is complicated by differences in the gene organization between humans 
and rodent animal models2.  A gene duplication event occurred in the metallothionein 
gene family between rodents and primates.  Rodents express four MT isoforms, MT1, 
MT2, MT3 and MT4 while all primates to date possess multiple copies of the MT1 
isoform2.  In contrast to the 4 rodent MT isoforms, 18 human MT isoforms and 4 human 
MT-like genes have been identified, most of which contain only small differences in 
specific amino acids.  The duplication event was at the level of DNA since all active 
genes contain an intact promoter.  Currently, there are at least 11 active human MT 
genes; MT4, MT3, MT2A, MT1A, MT1B, MT1E, MT1F, MT1G, MT1H, MT1M and MT1X.  
Seven of the MT isoforms are classified as non-processed pseudogenes (MT1IP, MT1P2, 
MT1JP, MT1L, MT1CP, MT1DP, and MT2P1); although it is not clear if some of the 
proposed pseudogenes are functional2.  The MT1JP and MT1DP genes contain a 
promoter and are transcribed, but they also encode a premature stop codon.  
Seventeen of the 18 isoforms are clustered together on chromosome 16q13 and 
chromosome 16 is known to be enriched for intrachromasomal duplications2.  The 
various MT isoforms do differ in their patterns of expression.  In general, the MT3 and 
MT4 are constitutively expressed in a narrow range of cell types; whereas, the MT1 and 
MT2 isoforms are highly inducible and constitutively expressed upon stimulation.  The 
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human MT1 isoforms show less divergence from human MT2 than from mouse MT1 
based on the coding sequences of the genes, suggesting that the MT1 and MT2 isoforms 
arose after the emergence of primates9.  In contrast, phylogenetic analysis of the mouse 
and human MT3 and MT4 isoforms proteins suggest that these isoforms diverged prior 
to the primate/rodent divergence2.  Both the human and mouse MT1 and MT2 isoforms 
are clearly distinct from the MT3 and MT4 clusters, in line with the unique tissue 
distributions and inducibility of the two sets of isoforms.   
 MT gene expression is known to be induced by oxidative stress and metal ions 
which suggests that MTs are an important component in the cells protection against and 
recovery from environmental insult, specifically those associated with heavy metals10-14.  
MT isoforms are ubiquitous and basally expressed at low levels but are also inducible by 
cytokines, xenobiotics and hormones15-17.  MT expression has also been implicated to 
play a role in many types of diseases including cancers, Alzheimers disease (AD), 
amyotrophic lateral sclerosis (ALS), autism, Parkinsons disease (PD), and even prion 
disease18-23. 
MTs in Cancer 
Although MTs have shown to be associated with various diseases, their 
association with cancers is predominantly reported.  MTs have been shown to have 
either increased or decreased expression in a tissue-dependent manner in 
carcinogenesis with no general consensus of expression levels seen for all cancer types.  
The mRNA and/or protein for MTs has been shown to be overexpressed in cancers of 
the human kidney, urinary bladder, breast, ovary, pancreas, testes, lung, nasopharynx, 
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leukemia, and non-Hodgkin's lymphoma (NHL)24.  On the other hand, a decreased 
expression of MT mRNA and/or protein has been shown in cancers of the human colon, 
liver, thyroid, central nervous system (CNS), and prostate24.  The level of increased or 
decreased expression of MT isoforms in these tumors has been suggested to have a 
relationship with tumor growth, prognosis, and/or patient resistance/response to 
cancer treatments24.   
MT Isoforms: Potential Biomarkers of Cancers 
On an MT isoform-specific basis, human MT-3 was first considered to be brain-
specific in expression but was shown to be expressed (mRNA and protein) in normal and 
malignant kidney and bladder, and quantifying levels of this MT isoform and/or other 
isoforms in the urine or tissue may be of potential use as a prognostic marker of tumor 
progression19-22.  Clinically, breast tumors are routinely immunohistochemically stained 
and classified as ER+ or ER- depending on the presence (ER+) or absence (ER-) of the 
estrogen receptor, and patients with ER- tumors tending to have worse patient 
prognosis due to tomoxifen resistance.  The ER status of the tumor is a good prognostic 
biomarker of breast cancers but ~25% of tumors will not stain exclusively ER+ or ER- and 
the pathologist will classify the tumor as “unknown ER status”.  In these patients, the 
chemotherapeutic regimen is not entirely clear and some individuals may get treated 
with drugs that will not aid in treating the disease but actually make them sicker.  In 
these cases it would be beneficial to have an alternative biomarker for use as a 
prognostic marker or help guide the therapeutic decisions and the MT status could 
potentially be this type of marker.   MT-1E mRNA has been shown to be highly 
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expressed in ER- human breast cells and invasive ductal breast cancer tissue compared 
to absent or low expression of MT-1E mRNA in ER+ cells and tissue29, 30, suggesting a 
relationship between this gene and the estrogen receptor status of the tumor cells.  In a 
larger study that suggests MT-2As association with cell proliferation in breast cancer, 
MT-2A  transcript was the highest among all other MT isoforms detected in seventy-nine 
cases of human invasive ductal breast carcinoma and the total MT protein was 
significantly higher in histological grade 3 compared to grade 1 and 2 tumors31.  These 
are a small sub-set of examples but specific MT isoforms have been hypothesized to play 
roles or be potential biomarkers in many cancers.  Taken together, the MT isoforms are 
an attractive biomarker in the clinical and toxicological community. 
Diagnostics and MT Protein Isoforms 
A major factor compromising the study of the role of the individual MT isoforms 
in human disease is the lack of isoform-specific antibodies to the individual MT family 
proteins.  Due to similarities in amino acid sequence, the only isoform-specific antibody 
that can be produced is against the MT-3 isoform32.  However, there is an antibody 
(Dako, clone E-9) that recognizes all the MT1, MT2 and MT4 protein isoforms that has 
been widely used for the histochemical determination of the expression of this family of 
proteins in cells and tissues33.  In fact, it is research using the E-9 antibody that has 
identified the need to develop methodology to quantify the individual MT isoform 
specific proteins.  The E-9 antibody against the human MT1, 2 and 4 family members has 
been widely used to demonstrate the immunohistochemical overexpression of MT in a 
wide variety of human cancers and has been the subject of several excellent reviews33-
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35.  In general, the overexpression of MT in various cancers, as determined using the E-9 
antibody, has been associated with resistance to anticancer therapies and linked to a 
poor prognosis.  While there is methodology to determine the expression of mRNA from 
the individual MT isoform genes36, 37, there are no available methods to determine the 
individual expression of the isoform-specific proteins in cells and tissues.  This prevents 
studies to determine if the expression of individual MT proteins may have diagnostic 
and prognostic significance beyond that found for the family members as determined as 
an undefined group of proteins or through their mRNA expression patterns.  The goal of 
the present study was to develop a proteomic method to identify and quantify the 
individual proteins that comprise the human metallothionein gene family. 
MT Proteomics 
 The N-terminal tryptic peptide of each human MT isoform has a unique 
sequence that may be used for their identification and quantification in complex 
biological samples from human cells and tissues38 (Table 1).  Any attempt at 
quantification of this family of small, highly conserved, cysteine rich proteins therefore 
requires reproducible detection of these signature peptides.  A number of studies have 
shed light on the nature of the N termini of MT isoforms which help inform the design of 
their mass spectrometry-based quantitation.  In the 1970’s and 1980’s, Edman 
sequencing of several mammalian MTs demonstrated that its N-terminal methionine 
was acetylated39-43.  This conclusion is consistent with more recent general studies of N-
termini which show that proteins beginning with Met-Asp, such as human MTs, are 
almost completely acetylated44-46.  Other studies utilizing capillary electrophoresis 
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Table 1.  Amino acid sequence alignment of human MT isoforms.  Tryptic peptides that 
are unique to an isoform and that are ≥ 6 residues with mass ≥ 800 Da are shown in red.  
Residues that differ from the consensus sequence are highlighted in grey.  Asterisks 
indicate invariant residues among MT1 and MT2 isoforms.  All proteins are shown with 
N-terminal acetylation. 
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and mass spectrometry detected trace amounts of unacetylated MTs47-50.  The fraction 
of unacetylated MT2 reached 20% in livers of zinc-treated rats48.  Though a minor form, 
unacetylated MT may have physiological relevance since its metal-binding properties 
are distinct from the acetylated form49.  Taken together, MTs are likely 
stoichiometrically N-acetylated except possibly under metal-stressed conditions when a 
minor degree of under-acetylation may be observed. 
Structural studies based on Edman sequencing or amino acid analysis do not 
address whether the N-terminal methionine might be oxidized. This is likely because of 
reversion of methionine sulfoxide to methionine under the acidic conditions of these 
procedures51, 52 or because cyanogen bromide may not have cleaved the N-terminal 
methionine sulfoxide53 preventing Met-oxidized MTs from being sequenced. 
In more recent years a few mass spectrometry-based studies have succeeded in 
identifying the complement of MT isoforms in human cells38, 54.  Though top-down 
approaches hold promise for quantitation of MTs based on the unique masses of intact 
isoforms38, 55, this has yet to be exploited.  Bottom-up quantitative approaches 
specifically targeting MTs have not yet been reported.   
Detection of MT peptides, especially the critical N-terminal peptides, appears to 
be sporadic in global proteomic profiling studies.  A survey of the Human 2012-10-11 
build of the PeptideAtlas database56, 57 reveals that N-terminal MT peptides are 
identified in only ten of 467 samples in the repository.  Seven of the data sets have been 
published58-62.  Combined, these studies identified three MT N-terminal peptides (MT-2, 
MT-1E, MT-1X).  Only one study detected the acetylated forms of MT-1X and MT-1E59. 
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The rest detected only unacetylated forms because N-terminal protein acetylation was 
not selected as a variable modification as a parameter for database searches.  
Even when N-terminal acetylated proteins are specifically targeted for profiling, 
detection of MT peptides is still limited to MT-2 and MT-1X46.  The COFRADIC (combined 
fractional diagonal chromatography) approach that has been successfully applied to the 
mass spectrometric characterization of many blocked N-termini63, 45 unfortunately 
excludes acetylated N-terminal MT peptides because the method requires cleavage at 
arginine residues which are absent from all human MTs except MT-4.   
Since human MT isoforms are distinguished by only one to three tryptic peptides 
(Table 1), the label-free methods utilized by the two PeptideAtlas-referenced studies 
that reported MT abundance58, 59 are not sufficiently robust for their accurate 
quantitation even if N-terminal acetylated peptides are measured.  Accurate 
quantitation is further compromised in global studies that do not incorporate N-
terminal acetylation into their search parameters.  One can conclude from this survey 
that most global proteomic profiling strategies are not optimized for MT quantification 
and may even yield misleading results.  In order to develop a robust peptide-based 
quantitative profiling strategy, existing LC-MS approaches needed to be optimized for 
this family of proteins. 
Given the high cysteine content of the N-terminal MT peptides, the use of 
isotopically labeled alkylating agents as a means of introducing mass tags for 
quantitative profiling was chosen. The demonstration that deuterated acrylamide could 
be used as a cysteine-directed mass tag for proteomics64 and the development of the 
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commonly used iodoacetamide-based “isotopic-coded affinity tags” (ICAT) method of 
quantitative analysis65 spurred the development of numerous variants of isotopically-
labeled alkylating agents66-71, all potentially applicable to quantitative proteomics of 
MTs.  Some of these agents, particularly the deuterated compounds have the 
disadvantage of isotope effects that may cause differences in chromatography72, 73, 
making them less desirable for LC-MS/MS-based quantitative profiling.  Others are not 
commercially available.  All of these alkylating agents give mass shifts of from 3 to 7 Da, 
which is reasonable for singly or doubly modified peptides.  Mass shifts for N-terminal 
MT peptides would be five times as great, and any isotope effects would be magnified 
accordingly. 
11 
 
STATEMENT OF PURPOSE 
 The first goal of this study was to develop a mass spectrometry-based method of 
identifying metallothionein isoforms in complex cell or tissue lysates.  The second goal 
of this study was to develop a means to quantify (relative and absolute) MT isoforms in 
complex cell or tissue lysate using mass spectrometry.  Furthermore, I wanted to apply 
this assay to quantify inductions of MTs from metal treatment.  I also wanted to develop 
a method for extracting MTs from urine then quantifying levels which has biomarker 
potential of renal or bladder cancer.  Lastly, I wanted to apply this assay in malignant 
and non-malignant breast cells with differing estrogen receptor status.  Since MTs have 
been widely used diagnostically, they may be a good place to look for 
prognostic/diagnostic biomarkers for cancers or heavy metal exposure. 
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CHAPTER II 
Methods 
Materials and Reagents - 15N-iodoacetamide, 14N-iodoacetamide, absolute ethanol, 
EDTA, urea, sodium chloride, Tris, dimethyl sulfide, xylene, tris(2-
carboxyethyl)phosphine and dithiothreitol  was from Sigma-Aldrich (St. Louis, MO).  SDS 
was from Bio-Rad (Hercules, CA).  RapiGest SF was from Waters Corporation (Milford, 
MA).  Human urine (freeze-dried)- KOVA-Trol III was from HYCOR Biomedical (Garden 
Grove, CA).  Microcon Centrifugal Filter Devices were from Millipore Corporation 
(Bedford, MA).  Formic acid was from Thermo Scientific (Waltham, MA).  MS-grade 
water, acetonitrile, and methanol were from Fisher Scientific (Pittsburgh, PA).  Pure 
intact MT-3 was from Bastenbalt (Tallinn, Estonia).  Isoform-specific N-terminal 
acetylated MT peptides were synthesized by Elim Biopharmaceuticals (Hayward, CA). 
Cell Culture-  
Human Prostate Cells- The RWPE-1 cells were obtained from the American Type Culture 
Collection (ATCC, Manassas, VA).  The RWPE-1 cells were grown in keratinocyte serum-
free medium (K-SFM) containing 50 μg/ml bovine pituitary extract and 5 ng/ml 
epidermal growth factor.  Cultures were incubated at 37 °C in a humidified atmosphere 
containing 5% CO2. The cells were fed fresh growth medium every 3 days and at 
13 
 
confluence the cells were subcultured at a 1:4 ratio using trypsin-EDTA (0.05%, 0.02%).  
For use in experimental protocols, cells were subcultured at a 1:4 ratio in T-75 flasks, 
allowed to reach confluence, and then exposed to 75 µM zinc sulfate for 4 days.  The 
cells were fed fresh medium containing zinc on day 3 and harvested for total protein or 
RNA on day 4. 
Human Kidney Cells- Epithelial HK-2 cells containing the stably transfected human MT-3 
were grown as described previously74, 75.  The cells were allowed to reach confluency 
with doming.  After cells domed they were maintained for three days in the presence or 
absence of 9 µM CdCl2 to induce the expression of metallothioneins.     
Human Breast Cells- Five breast cell lines (MCF-10A, MCF-7, T-47D, Hs578T, MDA-MB-
231) were obtained from the American Type Culture Collection.  The MCF-10A cells 
were grown in a 1:1 mixture of Ham’s F-12 medium and DMEM supplemented with 5% 
(v/v) fetal calf serum, 10 µg/ml insulin, 0.5 μg/ml hydrocortisone, 20 ng/ml epidermal 
growth factor, and 0.1 μg/ml cholera toxin.  The MCF-7, T-47D, Hs578T, and MDA-MB-
231 cells were grown in DMEM supplemented with 5% (v/v) fetal calf serum.  The cells 
were fed fresh growth medium every 3 days, and at confluence (normally 6-12 days post 
subculture), the cells were subcultured at a 1:4 ratio using trypsin-EDTA (0.25%, 1 mM). 
Cytosol Preparation - All data from cells listed above represent biological replicates 
done in triplicates.  Cell monolayers from two T-75 flasks were washed twice with 
phosphate-buffered saline (PBS), detached by scraping, and pelleted by centrifugation 
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at 197 x g for 5 min at 4°C.  Cell pellets were either stored at -80˚C or used immediately.  
Cells were resuspended in 0.5 mL of hypotonic buffer (10mM Tris pH 8.0, 1.5 mM MgCl2, 
10 mM KCl, 1 mM DTT, and 0.5 μL protease inhibitor cocktail (Sigma-Aldrich).  The cells 
were then passed through a 25-gauge, 5/8 inch needle three times to disrupt 
membranes.  The nuclei were pelleted by centrifugation (800 x g for 10 min at 4°C) and 
the supernatant was further clarified by centrifugation at 100,000 x g, 30 min at 4°C.  
Total protein was determined by the Bio-Rad Protein Assay (Bio-Rad, Hercules, CA).  
Typical yields of 0.5 mL cytosol per two T-75 flasks containing 3.0-3.5 mg/ml protein 
were obtained.  Cytosols were stored at -80 °C. 
Human Kidney and Brain Tissue- Data from these tissues represent three technical 
replicates of one biological replicate.  Frozen cortical kidney tissue and cerebrum brain 
tissue was also used in these studies.  The frozen kidney tissue came from an elderly 
renal cancer patient’s kidney that was removed due to cancer.  The kidney tissue came 
from healthy cortex of the diseased organ.  No data was available for the human brain 
tissue.  Tissues did not have patient identifiers.  A small piece of these tissues was 
manually homogenized and processed in hypotonic lysis buffer as listed above to extract 
cytosolic protein.  
Reconstituted Human Urine- Methods for total protein extraction from urine were 
analyzed to discover the most efficient way to extract MTs from this biological fluid and 
look for potential modifications of the MT proteins or peptides.  Freeze dried human 
urine (KOVA-Trol III-HYCOR Biomedical (Garden Grove, CA)) was purchased and 
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reconstituted in H2O for use in development of MT protein extractions.  Methanol 
precipitation showed highest recovery of protein.  Briefly, 5 µgs of intact pure 
unacetylated MT-3 was spiked into 1 ml of urine or MS-grade H2O for a control.  The 
samples were then incubated for 5 hours at 37 ˚C in a water bath to mimic conditions in 
human bladder.  Samples were centrifuged immediately at 10,000 X g at 4 ˚C to remove 
particulate matter and cell debris.  Pelleted material was discarded and supernatant was 
transferred to a fresh tube.  100% stock solution of methanol was added to urine at a 
ratio of 9:1.  3.5 mM EDTA was added to chelate any metals bound to MTs and to aid in 
their precipitation.  The samples were then incubated overnight (12-16 hr.) at -20 ˚C 
then centrifuged at 14,000 X g for 30 mins. at 4 ˚C.  Methanolic supernatant was 
decanted off and protein pellet was resuspended in MS-grade H20 and transferred to 
fresh eppendorf tube.  Ultrafiltration (3000 Da MWCO membrane) was also used as an 
extraction method for MTs in the urine according to the manufacturer’s instructions.  
After extraction of total urine protein, the concentration of the protein was estimated 
by area under curve analysis by 214 nm absorbance.  The protein was then either 
analyzed immediately as described below or stored at -80 ˚C. 
Formalin-Fixed Paraffin-embedded Uterine Specimens- Slices of tissue (2 X 10 µM) 
were minced and placed in clean 1.5 ml Eppendorf tubes.  Paraffin was removed with 
three washes in 1 ml of pure (99.0+%) xylene, and rehydration was achieved with three 
washes each in 1 ml of 100, 90, and 70% absolute ethanol.  Uterine tissues were 
resuspended in 100 µl of 0.2% (w/v) RapiGest in 50 mM ammonium bicarbonate with 5 
mM DTT or 100 µL of Qproteome Extraction Buffer (Qiagen, Germantown, MD).  For 
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RapiGest protein extraction, the samples were vortexed aggressively then incubated on 
ice for 5 min. and then mixed again by vortexing.  The samples were then incubated at 
100 ˚C for 30 min. then cooled on ice for 5 min. followed by vortexing vigorously.  The 
samples were heated at 80 ˚C for 2 hr. with agitation at 750 rpm followed by 5 min. 
incubation on ice.  Samples were then centrifuged for 15 min. at 14,000 X g at 4 ˚C.  The 
supernatant containing the extracted proteins was transferred to a new microcentrifuge 
tube.  A 10 µl aliquot was removed from samples to estimate protein concentration 
using a BCA assay.  The proteins were reduced, alkylated, and digested as described 
below.  After digestion the RapiGest surfactant was precipitated from samples with 
0.5% formic acid before LC-MS described below.  Extraction of proteins using the 
Qproteome kit was achieved by using the manufacturer’s standard protocol.  Filter-
Aided Seperation of Proteins (FASP) was required to remove detergent from the 
extracted proteins from the Qproteome kit before digestion and LC-MS.  Briefly, 50 µL 
of lysate was mixed with 200 µL 8M urea in 0.1M Tris pH 8.0 in the filter unit (YM-3) and 
was centrifuged at 14,000 X g for 30 min.  Then 200 µL of urea solution was added to 
the filter unit followed by centrifugation at 14,000 X g for 20 min.  The flow-through was 
discarded from collection tube and the recovered samples were reduced and alkylated 
as described below in the filter unit followed by centrifugation at 14,000 X g for 10 min.  
100 µL of the urea solution was added to the filter units followed by centrifugation at 
14,000 X g for 15 min., and then this step was repeated twice.  100 µL ammonium 
bicarbonate (ABC) was added to filter units, they were then centrifuged at 14,000 X g for 
10 min.  This step was repeated twice.  40 µL ABC with 2% trypsin was added to filter 
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units and incubated at 37 ˚C overnight.  The filter units were then transferred to new 
collection tubes and centrifuged at 14,000 X g for 10 min.  50 µL of ABC was added to 
filter units followed by centrifugation at 14,000 X g for 10 min.  The resulting peptides 
were used in LC-MS experiments as described below.      
Reduction and Alkylation of Cytosolic, Urine, and Fixed-tissue Protein – 300 µg of 
protein (~100 µl) was incubated with 3.5 mM EDTA.  Samples were then denatured with 
8 M urea, then reduced with 5 mM dithiothreitol (DTT) or tris(2-carboxyethyl) 
phosphine (TCEP) in 100 mM Tris pH 8.0 for 1 hour at room temperature in a final 
volume of ~190 µl.  Proteins were then alkylated at room temperature in the dark for 1 
hour by the addition of ~27 µl of 200 mM 14N- or 15N-iodoacetamide to a final 
concentration of 28 mM.  Urea and excess alkylating agent were removed from the 
samples by passing them through ~1 ml of Bio Gel P-6 in micro Bio-Spin chromatography 
columns (Bio-Rad Laboratories, Hercules, CA) equilibrated with 100 mM Tris pH 8.0. 
Preparation of 15N-labeled Peptide Standards -The purity of the seven metallothionein 
peptides as received from the manufacturer ranged from 11 to 90% even though >95% 
purity was requested.  This was primarily because of the difficulty of synthesis related to 
the high cysteine content and peptide-specific sequences.  Thirty µg of each peptide was 
reduced with 5 mM DTT or 5 mM TCEP in 100 mM Tris pH 8.0 for 1 hour at room 
temperature in a final volume of 31.5 µL.  The reduced peptides were then alkylated 
with 28 mM 15N-iodoacetamide for 1 hour in the dark at room temperature.  The 15N-
labeled peptides were then purified by reversed-phase chromatography using a narrow-
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bore 2.1 x 150 mm Zorbax 300SB-C18, 5-µm bead-size column (Agilent Technologies, 
Santa Clara, CA) on a Shimadzu 10-AVP HPLC (Shimadzu, Kyoto, Japan).  Peptides were 
separated with a linear 35 min gradient using 97% Buffer A (0.1% formic acid, 2% 
acetonitrile) to 38% Buffer B (0.1% formic acid, 98% acetonitrile) at 0.3 ml/min. Peptides 
were detected by absorbance at 214 nm.  The peak corresponding to the peptide with 
the correct mass as determined by mass spectrometry was collected, dried and 
reconstituted in MS grade H20.  All 
15N-labeled peptides were at least 95 % pure as 
assessed by rpHPLC.  Peptide concentration was determined using area under the curve 
analysis at 214 nm based on the absorbance of a known amount of MT peptide for 
which the peptide concentration using elemental analysis was provided by the 
manufacturer represented a product of >95% purity. Aliquots of the purified 15N 
absolute MT standard peptides were stored at -80°C.  A reference mixture containing 
145 pmol/μL of each of the seven 15N-labeled peptides (MT-2, MT-3, MT-1E, MT-1G2, 
MT-1X, MT-1M, MT-1F) served as the internal standard for absolute quantitation 
experiments in the HK-2 MT-3 cells.  For the breast cells, a reference mixture containing 
100 pmol/μL of each of the three 15N-labeled peptides (MT-2, MT-1E, MT-1X) was used 
as the internal standard for absolute quantitation. 
Trypsin Digestion - For relative quantification, 300 µg each of 14N-labeled control 
cytosol and 15N-labeled Cd-treated cytosol were combined.  For absolute quantification, 
1 µl of 15N-labeled MT peptide reference mix was added to 300 µg of 14N-labeled 
sample.  Samples were incubated with modified trypsin, 2% w/w (Trypsin Gold, 
Promega, Madison, WI) overnight at 37°C.  The reaction was stopped by the addition of 
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formic acid to 0.1% final concentration.  Peptides were desalted online via HPLC through 
a self-packed Magic C18AQ column (200A pore size, 5 micron diameter particles, 
MICHROM Bioresources, Auburn, CA) using 0.15 ml/min Buffer A (0.1% formic acid) for 
~20 minutes.  The peptides were then eluted onto a strong cation exchange (SCX) 
column using a 500 µl injection of 75% acetonitrile and 0.1% formic. 
Chromatography - Peptides were then fractionated on a 2.1 mm x 25 cm poly LC 
polysulfoethyl A self-packed SCX analytical column with a 60 min linear gradient using 
Buffer A (0.1 % formic acid) and from 0-25% Buffer B (0.1% formic acid; 1 M NaCl; 10% 
acetonitrile) at 0.15 ml/min.  Fractions were collected every seven minutes and 
screened by mass spectrometry to locate the MT peptides. The MT peptide-containing 
fraction was evaporated to dryness, and reconstituted in 24 µl 8 M HCl containing 0.5 M 
dimethyl sulfide. The reaction was incubated 30 minutes at room temperature to reduce 
methionine sulfoxides76. The reaction was then quenched by the addition of 12 µl 5 M 
NaOH. Precipitated salt was pelleted by centrifugation at 14,000 x g for 2 minutes at 
room temperature and the supernatant was collected. The sample was immediately 
injected into a self-packed 100 µm x 10 cm Magic C18AQ column (200A pore size, 5 
micron diameter particles, MICHROM Bioresources, Auburn, CA)  using a Tempo LC-
MALDI (ABI SCIEX, Framingham, MA) integrated nano-HPLC/spotter.  The column was 
equilibrated with 97% Buffer A (0.1% formic acid, 2% acetonitrile) and 3% Buffer B (0.1% 
formic acid, 98% acetonitrile) at a flow rate of 0.8 µl/min and peptides were 
fractionated with a 70 min linear gradient of 3% Buffer B/97% Buffer A to 20% Buffer 
B/80% Buffer A.  Fractions were spotted every 0.18 seconds onto a MALDI target plate 
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with post-column mixing of an equal volume of 10 mg/mL α-cyano-4-hydroxycinnamic 
acid (CHCA) in 75% acetonitrile, 0.1% formic acid.  The column was recycled with 70% 
Buffer B/30% Buffer A for 5 minutes and then re-equilibrated with 3% pump B for 10 
minutes. 
Mass Spectrometry - The samples were analyzed by MS and MS/MS using an ABI 4800 
MALDI-TOF/TOF mass spectrometer. For MS, laser intensity was 3200 to 3500 and 900 
spectra were accumulated over 30 subspectra at 30 shots per subspectrum.  The 
precursor ion mass range was limited to m/z 1800-3000. Resolution was typically 15000.  
Metallothionein peptide identities were confirmed by MSMS. Laser intensity was 4000. 
Spectra were accumulated over 30 subspectra at 30 shots per subspectrum.   
Unprocessed .t2d files were centroided and converted to .mgf files using the Peaks to 
Mascot tool on the AB Sciex 4000 Explorer software (version 3.5.28193). MT peptides 
were identified using Mascot version 2.3.02 (Matrix Science Inc., Boston, MA).  Spectra 
were searched against the human proteome in the UniProt protein database (version 
15.15).  Search parameters were set at precursor peptide mass tolerance of 1.2 Da; 
fragment ion tolerance of 0.6 Da; enzyme – trypsin; fixed modification - cysteine 15N-
carbamidomethylation; variable modifications - acetylation (protein N-term), 
methionine oxidation, cysteine 14N-carbamidomethylation; missed cleavages - up to 
two. Peptide mass errors were typically less than 100 ppm.  Mascot ion scores were 
routinely 60-150. 
Relative and absolute quantification - The mean monoisotopic peak intensity was 
determined for each MT 14N and 15N precursor ion across three to five spots spanning 
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the precursor ion peak. The minimum signal to noise ratio accepted for a given peak was 
20.  The mass difference between pairs of 14N- and 15N-labeled MT precursor ion pairs 
was 5 Da.  Intensities of the 15N-labeled monoisotopic peaks were corrected for the 
contribution of the overlapping 14N peptide n+6 isotopic peak using the equation 
 where H and L are the intensities of the 
monoisotopic peak of the heavy- and light- labeled precursor ions respectively, C is the 
percent contribution of the n+6 isotopic peak of the light precursor ion, P is the atom 
percent 14N contamination in 15N iodoacetamide, P’ is the atom percent purity of 15N 
iodoacetamide.  The 14N contamination was based on 99 atom percent according to the 
manufacturer. 
Real Time Analysis of MT Isoform mRNA Expression - Total RNA was purified from 
RWPE-1, HK-2 MT-3, MCF-10A, Hs578T, MDA-MB-231, MCF-7, and T-47D cell pellets 
(biological replicates done in triplicates) using the manufacturer’s standard TRI 
REAGENT (Molecular Research Center, Cincinnati, OH) protocol.  The measurement of 
MT isoform mRNA expression was assessed with real time RT-PCR utilizing previously 
described MT isoform-specific primers36.  The primers sequences used for MT-1M 
consisted of: Up- GGGCCTAGCAGTCG, Low- TGGCTCAGTATCGTATTG.  The primer 
sequences used for 18S mRNA expression were: Up- CGCCGCTAGAGGTGAAATTC, Low- 
TTGGCAAATGCTTTCGCTC.  Forty nanograms of total RNA was subjected to RT-PCR 
amplification using the iScript One-Step RT-PCR kit (Bio-Rad Laboratories, Hercules CA) 
with SYBR Green using 0.2 μM of primers in a total reaction volume of 20 μL in an 
iCycler iQ real-time detection system (Bio-Rad Laboratories).  Amplification was 
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monitored by SYBR Green fluorescence and compared with that of a standard curve of 
each MT isoform gene cloned into pcDNA3.1/hygro (+) and linearized with Fsp I.  Cycling 
parameters consisted of a reverse transcription step at 50 ˚C for 10 minutes, 
denaturation at 95 °C for 15 seconds, annealing at 65 °C for 40 seconds, and extension 
at 72 ˚C for 40 seconds which gave the optimal amplification efficiency of each standard.  
For MT-1M, 62 ˚C was used for the annealing temperature while the other cycling 
parameters listed above remained the same.  The level of MT isoform expression was 
normalized to that of 18S assessed by the same assay. 
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CHAPTER III 
Results 
Initial method development and detection of MTs in prostate cells 
The RWPE-1 cell line was used for the development of the method used to 
identify MTs in a complex lysate.  These cells were used based on prior experiments 
from our laboratory that demonstrated there is a large induction of MTs when these 
cells are treated with 75 µM zinc sulfate for four days.  The high levels of MTs in these 
cells would increase the likelihood of detecting MTs with MS.   
A major limitation to overcome in targeted MS experiments with complex lysates 
is ion suppression.  Ion suppression is defined as the simultaneous presence of more 
than one component in the ion source which can result in competition in the ionization 
process and lead to a subsequent reduction in MS signals.  Ion suppressors can be ionic 
species (electrolytes and salts), highly polar compounds (phenols or pigments), or 
various organic molecules (carbs, lipids, urea, metabolites, and peptides).  For 
proteomic studies, various top-down and/or bottom-up separation/enrichment 
techniques to overcome suppression can be employed to identify the proteins or 
peptides of interest.  Size exclusion chromatography (SEC), ion exchange (IEX), 
isoelectric focusing, and reverse-phase liquid chromatography (RPLC) are just a handful 
of examples employed to reduce sample complexity.   
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The very first technique used in this study to reduce sample complexity to enrich 
for and identify MTs was OFFGEL electrophoresis coupled with nano-rpHPLC (data not 
shown).  OFFGEL focuses proteins or peptides in solution according to their isoelectric 
points (PI).  Unfortunately, this technique was unsuccessful for a number of reasons.  
The chemical properties of the MT proteins or peptides inhibit the successful use of this 
technique.  Studying the sequences of the MT family of proteins revealed that the very 
first N-terminal tryptic peptide (T1) is required to distinguish all of the MT isoforms so 
isolating this peptide is imperative for successful identification of the MT isoforms 
(Table 1).  The main limitation with OFFGEL is the pH strips used to focus the proteins or 
peptides.  The strips have a limited pH range of 3-10 but in actuality the pH range 
focused is much narrower, such as 4-7.  This is a problem when it comes to using 
OFFGEL to focus MT peptides or proteins because the T1 peptide PI is very acidic (below 
the low pH range of OFFGEL) and the intact protein PI is basic (above the high pH range 
of OFFGEL).  So, the extreme pH range of the MT T1 or the intact protein isoforms 
prevent the successful use of OFFGEL as a first dimension separation technique.  
Ampholytes used in the OFFGEL experiments are another problem for LC-MS 
experiments.  Ampholytes are molecules that carry both acidic and basic groups and are 
used to help focus the peptides or proteins in OFFGEL experiments.  The problem is that 
they mimic peptides as well and are suppressive in LC-MS requiring special measures to 
remove them from samples. 
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After OFFGEL was deemed unsuccessful, it was necessary to develop an 
alternative enrichment strategy to detect the MT isoforms in cells or tissue.  Heat 
depletion of intact proteins was then used to enrich for MTs.  The physical properties of 
the MT proteins add attractiveness to this method.  MTs are very small and have been 
known to stay in solution when the sample is heated to 95-100 ˚C and this method has 
been used for years to isolate MTs.  If the MTs are bound to metals they are even more 
stable and resist precipitation.  Figure 1 displays the initial work flow used for detection 
of MTs in the RWPE-1 cells.  Early experiments with this technique involved preparing a 
cytosolic lysate in hypotonic lysis buffer (methods) then heating the sample to 95 ˚C for 
five minutes which precipitates the majority of intact proteins in the lysate.  Precipitates 
were spun out and proteins remaining in solution were treated with EDTA followed by 
reduction, alkylation, and tryptic digestion.  The resulting peptides were then separated 
based on their hydrophobicity using nano-rpHPLC and then analyzed by MS.  Figures 2 
and 3, respectively, show the reversed-phase chromatography of the peptide peaks 
based on 214 nm absorbance of the heat depleted control and Zn-induced cytosolic 
lysates.  There are clear differences in the chromatographic profiles of peptides of the 
control and Zn-induced samples.  The Zn-induced chromatograph displays multiple 
peaks early in the acetonitrile gradient that are absent in the control sample.  After the 
samples had been separated by nano-rpHPLC and spotted onto a MALDI target plate, 
the samples were analyzed by MS and MSMS. 
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Figure 1.  Initial work flow for identifications of human MTs from complex cell lysates.  
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Figure 2.  Liquid chromatography of control RWPE-1 cell tryptic peptides.  
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Figure 3.  Liquid chromatography of Zn-induced RWPE-1 cell tryptic peptides.
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Figures 4 and 5, respectively show the LC-MS heat maps of the sequenceable peptides 
within the control and Zn-induced lysates.  Again, there is a distinct difference when 
comparing the two heat maps.  The Zn-induced sample (Figure 5) has a high abundance 
of early eluting peptides that were identified using MSMS as being various MT peptides 
from multiple isoforms and also modified MT peptides (Figure 5, MT-zone).  A 
remarkable feature of the heat maps was that the MT peptides were segregated almost 
completely from the typical smaller early-eluting and larger more hydrophobic peptides 
(Figure 5).  Appendix B contains MSMS spectra and fragmentation tables for all MTs 
identified and studied in this project.  The only identifiable MT in the control sample 
(Figure 4) in these initial experiments was the higher abundant MT-2 isoform.  Figure 6 
displays an enlarged view of the MT zone of the LC-MS heat map from the Zn-induced 
sample.  Seven MT isoforms were identified in these Zn-induced heat depleted samples 
(MT-1E, 1F, 1G1, 1G2, 1X, 1M, 2) but there were also multiple modifications on these 
peptides (Table 2).  Some of the peptide modifications were endogenous (acetylated N-
term, +42 Da) but most were exogenous sample preparation artifacts such as ammonia-
loss of N-term cysteines (-17 Da), dethiomethylation (-48 Da) of methionine, truncations 
of 1 or 2 residues on N- and C-term (ΔM, ΔMD, ΔCA), and oxidation of methionine (+16 
Da).  The presence of these exogenous modifications needed to be resolved since 
quantitation was an eventual goal of this project.  Not only does having multiple species 
(modifications) of the same peptide affect reproducibility and accuracy of quantitation, 
it also limits the sensitivity of the assay. 
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Figure 4.  1D LC-MS heat map of control RWPE-1 tryptic peptides.  
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Figure 5.  1D LC-MS heat map of Zn-induced RWPE-1 tryptic peptides.  
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Figure 6.  Enlarged view of “MT zone” in Zn-induced RWPE-1 1D LC-MS heat map.
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Table 2.  Tryptic peptides identified for each MT isoform. 
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Figure 7.  1D LC-MS heat map of “MT zone” after optimization of sample preparation. 
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To resolve the unwanted modifications the entire sample preparation procedure 
had to be revised and optimized.  This required many experiments to optimize every 
step which required changes in pH, reagents, concentrations, temperatures, and 
incubation times.  The 95 ˚C heat depletion step was a very efficient way to enrich the 
MT peptides but it was probably the biggest catalyst of the unwanted modifications.  
After removing this step from the preparations, most of the unwanted modifications 
disappeared.  The optimized MT sample preparation and gradient conditions used for 
the remainder of this project is listed in the methods section.  Figure 7 displays a LC-MS 
heat map from a Zn-induced sample after optimization showing the MTs in mostly one 
form without the additional modifications.  After optimization, only three MT isoforms 
in the control cells could be identified, MT-2, 1E, and 1X (data not shown). 
N-terminal modifications of endogenous MTs 
 Almost all N-terminal peptides from endogenous MTs were N-acetylated.  A 
small amount of unacetylated MT2 (10% or less of total MT2 signal; not shown) was 
routinely detected in Cd-induced HK-2 cytosol.  A trace amount of unacetylated MT1E 
was observed once, but not for any of the other MTs.  In addition to acetylation, early 
experiments showed some truncations of the N-termini – most notably the loss of the 
acetyl-Met-Asp dipeptide (Table 2).  Refinement of the isolation and enrichment 
strategy greatly reduced the relative intensities of these truncated precursors, 
suggesting that they may have been artifacts of sample preparation.  The acetyl-Met-
Asp dipeptide of mammalian MTs precedes a proline residue.  The Asp-Pro bond in 
general78 and that of mammalian MTs in particular42, 41 are acid labile.  This 
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susceptibility to cleavage may explain in part why multiple N-terminal MT truncations 
are observed in the PeptideAtlas database56, 57.  As much as 40% of the total ion signal 
for a given N-terminal MT peptide was in the Methionine sulfoxide form.  This is 
considered a high degree of oxidation based on a recent quantitative proteomic study of 
intracellular methionine oxidation in human Jurkat cells79.  As described earlier, the 
COFRADIC approach does not capture N-terminal MT peptides.  Even so, the acetyl-Met-
Asp-Pro sequence of MT N-termini would classify it as highly susceptible to oxidation 
based on sequence preferences revealed by this study.  The susceptibility of these 
peptides to oxidation was reinforced by the observation that addition of synthetic MT 
peptides to cytosol caused them to achieve a similar degree of oxidation as the cognate 
peptides from endogenous MTs.  This oxidation appeared to occur before the 
chromatography steps.  Further experiments are needed to determine if methionine 
oxidation of MTs occurs intracellularly or if it is a sample handling artifact.  For purposes 
of quantitation, it was important to control for the potential variability of methionine 
oxidation in MTs.  Reduction with dimethyl sulfide80, 76 quantitatively reverted 
methionine sulfoxides to methionine, collapsing the MT zone into single dominant 
precursors for each isoform.   
Identification of endogenous N-terminal MT peptides in HK-2 MT-3 cells 
 The next step of this project was to characterize a cell line (HK-2 MT-3) that was 
expressing the MT-3 isoform.  Optimized one-dimensional reversed-phase 
chromatography followed by mass spectrometry was sufficient to identify seven MT 
isoforms in Cd-induced HK-2 human kidney epithelial cell cytosol (Table 3) and  
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Table 3. Unique N-terminal Acetylated Tryptic MT Peptides Detected in HK-2 MT-3 Cells. 
 
The five conserved cysteine residues are highlighted in red and the N-terminal 
methionine (acetylated) residues are highlighted in blue. The masses are listed for the 
fully alkylated 14N and 15N peptides along with elution times. 
Isoform Sequence Modifications Identified by Mascot 
m/z +1H 
(
14
N-C) 
(
15
N-C) 
Ret. 
(min.) 
MT-1E MDPNCSCATGGSCTCAGSCK 
Acetylation (protein N-term),  
5 Carbamidomethylations (
14
N- or 
15
N-C) 
2222.8 
2227.8 
36.9 
MT-1F MDPNCSCAAGVSCTCAGSCK 
Acetylation (protein N-term),  
5 Carbamidomethylations (
14
N- or 
15
N-C) 
2234.8 
2239.8 
46.9 
MT-1G2 MDPNCSCAAGVSCTCASSCK 
Acetylation (protein N-term),  
5 Carbamidomethylations (
14
N- or 
15
N-C) 
2264.8 
2269.8 
47.2 
MT-1M MDPNCSCTTGVSCACTGSCK 
Acetylation (protein N-term),  
5 Carbamidomethylations (
14
N- or 
15
N-C) 
2294.8 
2299.8 
45.6 
MT-1X MDPNCSCSPVGSCACAGSCK 
Acetylation (protein N-term),  
5  Carbamidomethylations (
14
N- or 
15
N-C) 
2246.8 
2251.8 
48.4 
MT-2 MDPNCSCAAGDSCTCAGSCK 
Acetylation (protein N-term),  
5 Carbamidomethylations (
14
N- or 
15
N-C) 
2250.7 
2255.8 
38.5 
MT-3 MDPETCPCPSGGSCTCADSCK 
Acetylation (protein N-term),  
5 Carbamidomethylations (
14
N- or 
15
N-C) 
2418.8 
2423.8 
45.1 
39 
 
(Appendix B).  Only three isoforms could be detected in cytosol from uninduced cells 
and their signals were very weak (Figure 8).  A second chromatography step was needed 
to reduce sample complexity and get better sampling depth.  Strong cation exchange 
(SCX) chromatography effectively separated the MT peptides, which eluted early in the 
gradient away from the bulk of tryptic peptides (Figure 9).  This result was consistent 
with the general SCX fractionation pattern of N-terminally acetylated peptides77.  The 
two-dimensional separation of uninduced HK-2 samples increased the sensitivity 
sufficiently to detect all of the MTs found in the Cd-induced sample except MT-1M 
(Figure 10).  Increasing the starting amount of cytosol from 300 ug to 800 ug did not 
produce additional detections of N-terminal MT peptides (data not shown). 
Validation of 14N and 15N iodoacetamide for quantitation of N-terminal MT peptides 
The enhanced sensitivity gained with two-dimensional LC and the simplification 
of precursor ion complexity with dimethyl sulfide treatment set the stage for 
quantitative profiling of MT isoforms.  We selected 15N-iodoacetamide as a stable 
isotope labeled compound because it is commercially available, gives a cumulative mass 
shift of 5 Da for N-terminal MT peptides, and is well-characterized for its cysteine-
specific reactivity in peptides.  To our knowledge this reagent has not been used in 
typical stable isotope labeling experiments probably because a single Dalton mass shift 
would complicate quantitation due to the high degree of isotopic envelope overlap. 
The commercially available 13C2-iodoacetic acid was also tested.  This compound 
gave a cumulative mass shift and no isotope effects were observed (not shown).  The 
increased hydrophilicity introduced by the carboxylates weakened their retention  
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Figure 8.  1D LC-MS heat map of “MT zone” in control HK-2 MT-3 cells.  
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Figure 9.  Strong cation exchange chromatography profile.  Optimized strong cation 
exchange (SCX) chromatography of tryptic digested cytosolic lysate with ~100 
pmol/isoform pure acetylated N-term MT peptide standards added.  Fractions two and 
three (7-21 mins.) contain the acetylated N-term tryptic MT peptides along with other 
non-MT 0 and +1 charged peptides.  The red line indicates NaCl gradient.  The black line 
indicates 214 nm absorbance of the tryptic peptides. The acetylated N-term MT 
peptides elute with ~20-25 mM NaCl.  
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Figure 10.  2D LC-MS heat map of “MT zone” in control HK-2 MT-3 cells.  
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during reversed phase chromatography sufficiently to compromise reproducible 
quantitation.  300 µgs of cytosol from the Cd-induced HK-2 cells were alkylated with 14N-
iodoacetamide (light) and 300 µgs of the same cytosol was alkylated with 15N-
iodoacetamide (heavy), respectively.  Equal amounts of alkylated samples were mixed 
and proteins were digested with trypsin.  The N-terminal MT peptides were enriched as 
described in Methods and analyzed by MALDI-TOF/TOF MS.  Figure 11 illustrates the 
isotopic envelopes for the light and heavy labeled N-terminal acetylated tryptic peptides 
of MT-2 precursor ions.  As expected, a 5 Da shift between the light (m/z 2250.7) and 
heavy (m/z 2255.7) monoisotopic peaks was observed.  The monoisotopic peak 
intensities for the light and heavy precursors were plotted after correcting for isotopic 
overlap and purity of the 15N label (Figure 12).  The 1:1 ratio of light to heavy 
monoisotopic peak intensities across the entire MT-2 peak indicates that there is no 
isotope effect on the chromatographic behavior of the light and heavy-labeled MT 
peptides.  This reproducibility was maintained for all observed N-terminal MT peptides 
(Figure 13).  The sensitivity and dynamic range of the relative quantitation assay was 
determined next.  A serial dilution of light cytosol was mixed with a constant amount of 
heavy cytosol and the samples were digested, fractionated and analyzed as before.  A 
1:1 correlation was observed for experimental vs. theoretical light/heavy MT2 ratio over 
two orders of magnitude (Figure 14).  The signal to noise ratio for these samples ranged 
from 3.24 to 109.33.  The signal-to-noise ratio of the weakest observed endogenous N-
terminal MT peptide was 3.24 for MT-1G2. 
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Figure 11.  MS spectra of 14N and 15N labeled N-term acetylated MT-2 peptide in HK-2 
MT-3 cytosol.  The isotopic envelop of the light-labeled peptide is outlined in black while 
the isotopic envelop of the heavy-labeled peptide is outlined in red.  
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Figure 12.  Retention time vs. monoisotopic peak intensity of N-term acetylated MT-2      
peptide in HK-2 MT-3 cytosol.  The black points represent data from the light-labeled 
peptide while the red points represent data from the heavy-labeled peptide after de-
isotoping spectra.  
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Figure 13.  3D nano-rpHPLC-MS heat map of the MT zone showing the 1:1 (14N:15N)          
labeling MT peptides in HK-2 MT-3 cytosol.  The black cones represent data from the 
light-labeled peptide while the red cones represent data from the heavy-labeled 
peptide.  
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Figure 14.  Sensitivity and dynamic range of MT-2 relative quantitation.  
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Cd-induction of MT isoforms in HK-2 MT-3 cells: Relative quantitation 
 In order to determine the fold induction of individual MT isoforms in response to 
Cd treatment, equal volumes of HK-2 cytosol from control (light) and Cd-induced (heavy) 
cells were mixed, trypsin-digested, fractionated and analyzed as above.  Figure 15 is a 
representative three-dimensional LC-MS heat map of the MT zone.  The fold induction 
were calculated for six MT isoforms (Figure 16).  A value could not be calculated for MT-
1M since it was not detected in control cells.  The range of inductions for MT1/2 
isoforms was 1.7 to 12-fold with MT-1F showing the highest induction.  The MT-3 
isoform, under the control of the non-metal-responsive CMV promoter, was induced 
1.70-fold.  Figure 17 displays the fold inductions (ratio of heavy/light) compared to the 
average monoisotopic peak intensities of the six MT isoforms measured by the relative 
assay.  In proteomics, relative abundance of proteins or peptides is commonly estimated 
(sometimes inaccurately) by the relative peak intensities (assuming equal ionization of 
each MT peptide).  Assuming that all the diagnostic N-term acetylated MT peptides 
ionize similarly, Figure 17 demonstrates that MT-2 was the most abundant peptide in 
both the control and Cd-induced cells and that MT-1G2 was the least abundant in both 
these cells.  According to peak intensities, MT-1F showed equal abundance to MT-1G2 in 
the control cells but was the 4th most abundant peptide in the Cd-induced cells, which 
accounted for the 12-fold induction of this isoform. 
Synthetic N-terminal acetylated MT peptides for absolute MT quantitation 
 Table 4 (Appendix C) displays all the acetylated N-terminal tryptic peptides for 
human MT isoforms that were commercially synthesized, 15N-labeled, and purified  
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Figure 15.  3D nano-rpHPLC-MS heat map of MT zone in control (14N) vs. Cd-induced 
(15N) HK-2 MT-3 cytosol.  The black cones represent data from the control and the red 
cones represent data from the Cd-induced acetylated N-terminal tryptic peptides in HK-
2 MT-3 cells.  
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Figure 16.  Relative quantitation of MTs in HK-2 MT-3 cells exposed to 9 µM Cd for 3              
days.  Errors bars represent mean ± S.D. where n=3.  
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Figure 17.  Ratios (heavy/light) vs. monoisotopic peak intensities for MTs in control 
(black) and Cd-induced (red) HK-2 MT-3 cells.  
52 
 
Table 4.  All endogenous and synthetic human N-terminal tryptic MT peptides.  *m/z 
includes N-terminal acetylation and five 
14
N carbamidomethyl modifications of the Cys 
residues.  The 
15
N carbamidomethylated peptides have a m/z 5 Da greater than the m/z 
shown.  *ppm errors were consistently less than 50 for all MT isoforms in experimental 
runs.  N-terminal tryptic MT peptides account for 30-36% sequence coverage across all 
isoforms.  `MT-1G1 was not successfully synthesized but was endogenously detected in 
alternative cells and tissues. 
 
Acc. # MT 
Isoform 
Sequence Expected 
m/z 
* 
Retention 
Time 
(min.) 
P04731 MT-1A MDPNCSCATGGSCTCTGSCK 2252.8 36.5 
P07438 MT-1B MDPNCSCTTGGSCACAGSCK 2222.8 36.5 
P04732 MT-1E MDPNCSCATGGSCTCAGSCK 2222.8 37.0 
P04733 MT-1F MDPNCSCAAGVSCTCAGSCK 2234.8 46.9 
P13640 `MT-1G1 MDPNCSCAAAGVSCTCASSCK 2335.9 48.2 
P13640-2 MT-1G2 MDPNCSCAAGVSCTCASSCK 2264.8 47.2 
P80294 MT-1H MDPNCSCEAGGSCACAGSCK 2220.8 38.3 
Q93083 MT-1L MDPNCSCATGGSCSCASSCK 2238.8 35.8 
Q8N339 MT-1M MDPNCSCTTGVSCACTGSCK 2294.8 45.8 
P80297 MT-1X MDPNCSCSPVGSCACAGSCK 2246.8 48.4 
P02795 MT-2 MDPNCSCAAGDSCTCAGSCK 2250.8 38.5 
P25713 MT-3 MDPETCPCPSGGSCTCADSCK 2418.8 45.1 
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for this study.  Initially, the synthetic peptides were found to be of lower purity levels 
than what was requested (>95% purity) because the high cysteine level of these 
peptides made them very reactive.  The company synthesized the peptides and ran 
elemental analysis of the peptides to determine the absolute amount of the peptides 
before shipping them.  Table 5 lists the initial purity levels of the peptides that were 
ordered.  After alkylating (15N-labeling) these peptides, the peptides of interest were 
able to be purified-out from the contaminating synthesis products.  The identities of 
each 15N peptide were confirmed by MSMS (Appendix B) after re-purification.  During 
the purification process the total abundance of the pure peptides recovered was 
estimated by area under the curve analysis (AUC) using 214 nm absorbance.  After 
purification of all peptides, equal amounts of each isoform were mixed together then 
total MS ionizations were calculated for each (Table 5).  The ionization intensities of 
these peptides were comparable when analyzed in this experiment but there was still a 
2-3 fold difference for some of the peptides.  So, equal amounts of the purified peptides 
were re-run on the same nano-rpHPLC gradient and AUC analysis was re-calculated once 
more.  The re-calculated AUCs displayed similar 2-3 fold differences for the same 
isoforms that were seen in the total MS ionization experiment so a correction factor was 
calculated.  The correction factor was the normalization of the individual MTs AUCs to 
that of MT-1X because this isoform had the greatest initial purity (90%) and likely 
represents the absolute concentration most closely.  These 15N-labeled peptides would 
serve as absolute standards to quantify endogenous levels of the various MTs isoforms 
in cells and tissues. 
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Table 5.  Initial purities and total ionizations of synthetic peptides. 
 
Isoform 
Initial 
Purity (%) 
Total 
Ionization 
Normalized 
Ionization 
MT-3 73.32 265429.84 0.81 
MT-1L 34.52 294155.78 0.90 
MT-1X 90.28 325968.10 1.00 
MT-1H 17.65 234696.60 0.72 
MT-1E 44.86 273031.63 0.84 
MT-1B 34.65 273031.63 0.84 
MT-2 73.27 154424.32 0.47 
MT-1M 25.69 126377.40 0.39 
MT-1G2 10.15 138968.18 0.43 
MT-1F 12.84 163048.02 0.50 
MT-1A 11.01 110516.85 0.34 
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MT Isoform expression in HK-2 MT-3 Cells: Absolute protein quantitation 
The 15N-labeled synthetic MT peptides described earlier were used as internal 
standards to determine the absolute amount of human MT isoforms in HK-2 MT-3 cells.  
A cocktail containing seven N-terminal MT peptides observed in HK-2 MT-3 cells was 
added to cytosols that had been alkylated with 14N-iodoacetamide.  Figure 18 outlines 
the work flow for absolute quantitation.  The spiked cytosols were then trypsin-digested 
and the N-terminal MT peptides were enriched and analyzed as above.  Metallothionein 
isoforms were quantified for both control and Cd-induced cells (Figure 19, Table 6).  
Absolute abundance was expressed as ng intact MT isoform per µg of total protein.  300 
µg total cytosolic protein was used for each experiment.  This is equivalent to the 
cytosolic protein content of ~3.7 X 106 cells.  The protein expression for the seven 
detected MT isoforms ranged from 0.11 to 7.28 ng per µg total protein for MT-1F in the 
control and MT-2 in the Cd-induced cells respectively.  The six MTs detected in the 
uninduced cells accounted for 0.33% of total protein whereas the seven MTs detected in 
Cd-induced cells accounted for 1.46% of the total cytosolic protein.  The fold inductions 
of individual MT isoforms determined by the absolute method were comparable to 
those measured by the relative method (Figure 20, Table 7).   
MT mRNA transcript levels in the HK-2 MT-3 Cells 
 The mRNA expression of human MT isoforms in HK-2 MT-3 cells was determined 
by a quantitative polymerase chain reaction assay (Figure 21, Table 8).  The same MT 
isoforms were detected at the protein and mRNA levels with one exception.  A low level 
of MT-1M mRNA, not seen at the protein level, was detected in uninduced cells.  This  
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Figure 18.  Work flow for absolute quantitation.  
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Table 6.  Absolute quantitation values of MT proteins in HK-2 MT-3 cells.  Δ (no 
detection).  Values are average ng/µg ± S.D. and represent three biological replicates.  
Fold inductions were calculated by comparing levels of each MT isoform from Cd-
treated cells to that of the MT levels found in the control. 
 
 Control Cd-treated Fold Induction 
MT-1M Δ 0.3757 ± .1257 -- 
MT-3 0.6013 ± .0431 1.0544 ± .1550 1.8 
MT-1X 0.3486 ± .0639 1.6396 ± .2841 4.7 
MT-1G2 0.1513 ± .0212 0.8253 ± .1717 5.5 
MT-1F 0.1083± .0030 1.0742 ± .1912 9.9 
MT-1E 0.4150 ± .0181 2.4364 ± .1187 5.9 
MT-2 1.6955 ± .2169 7.2757 ± .5457 4.3 
 
 
 
Figure 19.  Absolute protein levels of the MT isoforms in HK-2 MT-3 cells.  Protein data 
represents biological replicates where n=3.  Error bars indicate the standard deviation 
around the mean.  A two-way ANOVA followed with a Bonferroni posttest was run on all 
data sets.  Significance was based on variation between control (black) and Cd-induced 
(red) levels for each isoform.  * P < 0.01.  Δ (no detection).  
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Table 7.  Fold induction values for MT protein and mRNA.  Fold inductions (protein and 
mRNA) from control to Cd-Induced HK-2 MT-3 cells were measured by relative and 
absolute methods.  Values are average fold inductions ± S.D. and represent three 
biological replicates.  
 
Protein mRNA 
 Absolute Relative Transcripts 
Isoform Fold Induction Fold Induction Fold Induction 
MT-3 1.7 ± 0.1 1.8 ± 0.2 1.7 ± 0.1 
MT-1X 5.6 ± 0.9 4.7 ± 1.8 5.1 ± 0.4 
MT-1G2 5.2 ± 0.5 5.4 ± 1.3 4.9 ± 0.6 
MT-1F 12.0 ± 2.8 9.9 ± 1.9 3.1 ± 0.3 
MT-1E 6.2 ± 1.1 5.9 ± 0.5 3.0 ± 0.4 
MT-2 4.8 ± 1.1 4.3 ± 0.9 3.1 ± 0.9 
 
 
Figure 20.  Fold induction comparison of MT isoform protein and mRNA.  
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Table 8.  Absolute quantitation values of MT mRNA transcripts in HK-2 MT-3 cells.  
Values are average MT transcripts/1000 18S ± S.D. and represent three biological 
replicates.  Fold inductions were calculated by comparing levels of each MT isoform 
from Cd-treated cells to that of the MT levels found in the control. 
 
 Control Cd-treated Fold Induction 
MT-1M 0.0021 ± .0006 0.0031 ± .0001 1.5 
MT-3 0.0013 ± .0002 0.0022 ± .0002 1.7 
MT-1X 0.0069 ± .0023 0.0351 ± .0084 5.1 
MT-1G2 0.0027 ± .0003 0.0135 ± .0008 4.9 
MT-1F 0.0027 ± .0004 0.0085 ± .0021 3.1 
MT-1E 0.1078 ± .0259 0.3265 ± .0572 3.0 
MT-2 0.0352 ± .0091 0.1090 ± .0265 3.1 
 
 
Figure 21.  Absolute mRNA transcript levels of the MT isoforms in HK-2 MT-3 cells.  
Absolute mRNA transcripts were normalized to 18S.  mRNA data represents biological 
replicates where n=3.  Error bars indicate the standard deviation around the mean.  A 
two-way ANOVA followed with a Bonferroni posttest was run on all data sets.  
Significance was based on variation between control (black) and Cd-induced (red) levels 
for each isoform.  * P < 0.01.  Δ (no detection).  
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level of concordance suggests that the mass spectrometry-based method has adequate 
sampling depth.  The relative order of MT isoform abundance differs somewhat 
between mRNA and protein expression.  For example, MT-1E mRNA is the most 
abundant whereas MT-2 protein levels are greatest.  Technical limitations associated 
with quantification of peptide standards may be partly responsible for this difference, 
but other factors such as isoform-dependent differences in protein stability may also be 
in play.  Cadmium-induced mRNA induction was comparable to that of protein for MT-
1G2, MT-1X, MT-2 and MT-3, but induction of protein expression was greater than that 
of mRNA for MT-1E, and MT-1F (Figure 20, Table 7).   
This suggests that MT isoforms may display differential post-translational 
stabilization upon metal induction.  The influence of metal binding on MT stabilization 
and proteolytic susceptibility must be considered since it has been shown that MTs 
bound to Cd are significantly more protected from degradation and proteolytic 
cleavage81-85.  Half-life measurements of MT isoform mRNAs and proteins are needed to 
address this possibility.  Lastly, the translational efficiencies of the individual MT 
isoforms are also something that needs consideration when comparing mRNA 
transcripts to protein levels. 
Absolute protein quantitation of MT isoforms in human tissue 
The next step of this study was to characterize MT levels in human tissue.  Two different 
types of human tissue were used to achieve this: normal kidney cortex and normal brain 
cerebrum.  The kidney tissue came from an elderly (~75 years old) patient’s kidney that 
had been removed due to cancer.  The actual tissue that was used in this study was 
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from a healthy part of the cortex of that kidney.  It is known that cadmium ingested 
through diet accumulates in the kidney and keeps accumulating over the life-time of an 
individual.  In a sense, it can be thought that this tissue represents what is happening in 
a low-level chronic exposure (decades) to cadmium compared to the HK-2 MT-3 cells 
exposed to a high-level acute exposure (3 days) which was previously explained.   
 Seven MT isoforms were detected in this tissue.  Figure 22 and Table 9 display 
the absolute protein levels of MT isoforms in human kidney tissue.  Interestingly, MT-
1G1 was the most abundant isoform present in this tissue (1.6 ng/µg) while this isoform 
was completely absent in the HK-2 MT-3 cells but its sub-isoform, MT-1G2, which only 
differs from MT-1G1 by a deletion of one alanine, was present at low levels in the Cd-
induced HK-2 MT-3 cells (0.8 ng/µg).   MT-1F was the least abundant MT isoform in the 
kidney tissue (0.2 ng/µg).  There is likely going to be some biological variation in the 
expression of MT isoforms from individual to individual and this data is only 
representative of one tissue but perhaps there is a potential role of the individual 
isoforms or sub-isoforms in relation to acute, chronic, high-dose, or low-dose exposures 
to cadmium.  More tissue needs to be analyzed to confirm or reject this.  The MT levels 
in normal human brain cerebrum were then analyzed.  It is well published that MT-3 is 
highly expressed in human brain so this tissue was characterized as a positive control 
tissue for the MT-3 isoform (Figure 23 and Table 10).  Six different MT isoforms were 
detected in this tissue.  MT-3 displayed this highest level of protein (4.1 ng/µg) being 4-
fold more abundant than the next highest abundant isoform, MT-2 (1.1 ng/µg).  Again, 
MT-1F was the lowest abundant (0.1 ng/µg) followed by MT-1G1 (0.2 ng/µg).  This  
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Table 9.  Absolute quantitation values of MT proteins in human cortex kidney tissue.  
Values are average ng/µg ± S.D. and represent three technical replicates. 
 
MT-1F 0.1620 ± 0.0099 
MT-1H 0.3982 ± 0.0835 
MT-1E 0.3413 ± 0.0140  
MT-1X 0.5571 ± 0.0152  
MT-1G2 0.3709 ± 0.0363 
MT-2 0.4382 ± 0.0195  
MT-1G1 1.5888 ± 0.1720  
 
Figure 22.  Absolute protein levels of the MT isoforms in human cortex kidney tissue. 
Protein data represents biological replicates where n=1.  Error bars indicate the 
standard deviation around the mean from 3 independent technical replicates of 1 
biological replicate.  A One-way analysis of variation was run on all data sets.  * P < 0.05, 
** P < 0.01, and *** P < 0.001.  
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Table 10.  Absolute quantitation values of MT proteins in human cerebrum brain  
tissues.  Values are average ng/µg ± S.D. and represent three technical replicates. 
 
MT-3 4.1242 ± 0.1065  
MT-2 1.0820 ± 0.0715 
MT-1E 0.8083 ± 0.0281 
MT-1G1 0.2381 ± 0.0056  
MT-1X 0.6257 ± 0.0141  
MT-1F 0.1084 ± 0.0003  
 
 
Figure 23.  Absolute protein levels of the MT isoforms in human cerebrum brain tissue.  
Protein data represents biological replicates where n=1.  Error bars indicate the 
standard deviation around the mean from 3 independent technical replicates of 1 
biological replicate.  A One-way analysis of variation was run on all data sets.  * P < 0.05, 
** P < 0.01, and *** P < 0.001. 
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confirms what others have reported of the abundance of MT-3 for this type of tissue but 
again this is only representative of one tissue sample and more samples need to be 
analyzed to adequately characterize this type of tissue. 
Extraction of pure intact MT-3 from human urine for proteomic analysis 
A side project of this study was to develop a method for extracting MTs out of urine for 
proteomic analysis, more specifically quantitation of the individual MTs in the urine for 
use as potential noninvasive biomarkers of renal cell carcinoma (RCC) or bladder cancer.  
There is evidence that MTs are over expressed in both bladder and kidney cancer and 
their under expression has been implicated in carcinogenesis.  Additionally, certain MT 
isoforms may only be present in malignant tissues of the bladder or kidney.  Measuring 
MT levels in the nearest biological fluid is an attractive means for developing a 
prognostic, diagnostic, and/or therapeutic decision-making biomarker of these diseases.  
Since a proteomic MT quantitation method was in place, the main problem that needed 
to be addressed with this part of the project was how to extract MTs out of the urine 
and also see if the protein or peptides were being modified by the urine since urine 
contains many salts, metabolites, vitamins, etc.  There are different ways of extracting 
proteins out of urine but finding the most efficient way to specifically extract MTs is 
paramount for reproducibility and significance of findings.  The need for reliable MT 
extraction is further amplified by the fact that urine is highly variable in protein content 
which is largely due to diet.  There were two main protein extraction methods that were 
compared in this study, an organic precipitation of proteins and ultrafiltration using a 
size exclusion membrane (3000 Da MWCO).  The details for these extractions are  
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listed in the Methods section.  Very briefly, 5 µg of pure MT-3 protein was spiked into 1 
ml of reconstituted human urine or then incubated for 5 hrs at 37 ºC to mimic conditions 
in the human bladder.  The protein was then extracted out of samples by each of these 
methods and was quantified through use of reversed-phase HPLC AUC analysis using 
214 nm absorbance.  A direct injection of 5 µgs of the pure protein was run to compare 
extraction efficiencies of the different methods.  The organic precipitation yielded the 
greatest recovery of the intact MT-3 protein (~72%) while the ultrafiltration method 
yielded a poorer recovery (~35%) which is about half the yield.  After extraction and 
measuring recoveries, the protein was digested with trypsin.  The peptides were then 
separated via nano-rpHPLC then MS and MSMS was performed.  The only modification 
seen from incubating the protein in urine was oxidation of methionine which was 
expected.  Ultrafiltration of urinary proteins is probably the most common technique for 
isolating proteins out of this fluid.  The reason this method was poor for MTs is still 
unknown.  Perhaps the MTs are leaking through the membrane during centrifugation or 
they may be interacting (sticking) to the membrane via the abundant cysteine residues.  
It may be worthwhile alkylating the cysteines before this step and retrying.  A reversed-
phase column extraction was also attempted which entails binding the urinary proteins 
to the column then washing and eluting the proteins off the column with acetonitrile.  
This method failed (no recovery of MT-3), however, 75 % acetonitrile was used to elute 
the intact proteins and perhaps this concentration irreversibly precipitated the proteins.  
This method should be revisited with a lower concentration of acetonitrile or a different 
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organic, perhaps methanol which has more hydroxyl groups that could potentially aid 
the proteins to re-solublize. 
All methods are limited to the volume of urine that can be processed.  The 
reversed-phase technique is attractive since large volumes could be passed through a 
column while still binding and concentrating the proteins. 
Proteomic analysis of formalin-fixed paraffin-embedded uterine specimens 
 Another side project of this study was to try proteomic analysis of formalin-fixed 
paraffin-embedded (FFPE) tissue with the hopes of eventually being able to identify and 
quantify MT levels in these specimens.  A big benefit of this type of tissue is that there is 
a lot of clinical data associated with these specimens that have been collected over a 
span of decades, such as patient treatments and outcomes.  FFPE tissue represents a 
valuable resource for retrospective studies and biomarker discovery.  Uterine FFPE 
specimens from hysterectomy patients were used for this work since there was more of 
this tissue available.  The FFPE tissues underwent immunohistochemistry prior to 
proteomic work to verify that MTs were in fact present in the tissues used for analysis 
(data not shown).   
There were two main methods tested for extraction of proteins out of FFPE 
tissue for proteomic analysis.  The first tested was a commercially available kit from 
Qiagen.  Proteins were extracted using the manufacturers standard protocol and 
recommendation of the amount of tissue to use for analysis (2 X 10 µM) sections.  The 
initial attempts failed using this technique (no MS identifications of proteins).  It was 
believed that the extracted proteins were directly LC-MS friendly but that was not the 
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case.  The contents of the extraction buffer were proprietary but the company 
confirmed that the extracted proteins could be used for MS analysis but special “clean-
up” steps were required before performing LC-MS. 
These initial attempts failed because there was likely detergent and a high 
concentration of reducing agent present in the extraction buffer.  Both are conditions 
that inactivate trypsin used for digestion.  It was necessary to add a FASP protocol  
(described in Methods) to remove any detergents or chemicals potentially interfering 
with LS-MS analysis. 
 After adding the additional “clean-up” protocol to the Qiagen protocol many 
protein identifications (>1000) were achieved using two-dimensional analysis (data not 
shown).  Unfortunately, there were zero MT protein identifications.  Additional attempts 
were made and even increasing the initial amount of tissue (3 X 10 µM) yielded the 
same result of no MT identifications.  Another FFPE tissue extraction method was 
attempted using a well-known proteomic-friendly detergent, RapiGest, yielded similar 
results to the Qiagen kit.  Again, this was attempted multiple times along with different 
amounts of protein, up to 3 X 10 µM tissue slices, and still zero MT identifications.  
There are potentially multiple reasons for these results.  The MTs may not be getting 
extracted out of the tissue (still cross-linked), the MTs may be getting washed away in 
sample preparation, they may be getting extracted but modified in a way that hampers 
trypsin digestion or ionization of the peptide, or there may simply not be enough of 
extracted proteins so doubling or tripling the starting amount of tissue may result in MT 
identifications.  In any case, more development and refinement of standard extraction  
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protocols is needed for MT analysis in FFPE tissue. 
MT isoform expression in malignant and non-malignant human breast cells with 
different estrogen receptor (ER) status: Absolute protein quantitation 
The last goal of this study was to apply this assay to four malignant (MCF-7, 
Hs578T, T-47D, and MDA-MB-231) and one non-malignant (MCF-10A) human breast cell 
lines.  The MCF-7 and T-47D cell lines are estrogen receptor positive (ER+) while the 
Hs578T and MDA-MB-231 cell lines are estrogen receptor negative (ER-).  The 15N-
labeled synthetic MT peptides described earlier were used as internal standards to 
determine the absolute amount of human MT isoforms in these breast cells.  A cocktail 
containing three N-terminal MT peptides observed in all breast cells (MT-2, MT-1E, and 
MT-1X) was added to cytosols that had been alkylated with 14N-iodoacetamide.  The 
spiked cytosols were then trypsin-digested and the N-terminal MT peptides were 
enriched and analyzed as above.  Metallothionein isoforms were quantified for control, 
ER+, and ER- cells (Figure 24, Table 11).  Absolute abundance was expressed as ng intact 
MT isoform per µg of total protein.  300 µg total cytosolic protein was used for each 
experiment which is equivalent to the cytosolic protein content of ~6.0 X 106 breast 
cells.  The protein expression for the three detected MT isoforms ranged from 0.05 (MT-
1X in T-47D cells) to 1.94 (MT-2 in Hs578T cells) ng per µg total protein accounting for 
just over a 38-fold difference in MT isoform abundance between the ER+ and ER- cell 
lines (Figure 24, Table 11).  The three MTs detected in the ER- Hs578T cells accounted 
for 0.25% of total cytosolic protein whereas the two MTs detected in ER+ T-47D cells 
accounted for 0.019% of the total cytosolic protein.  In the control (MCF-10A) cells,  
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Table 11.  Absolute quantitation values of MT proteins in human breast cells.  Values are 
average ng/µg ± S.D. and represent three biological replicates.  Relative changes were 
calculated by comparing levels of each MT isoform from each malignant cell line to that 
of the MT levels found in the control (MCF-10A).  Δ (no detection). 
 
  Relative  Relative  Relative 
 MT-1X Change MT-1E Change MT-2A Change 
MCF-7 .0754 ± .0079 1.1 Δ -- .1354 ± .0520 0.3 
T-47D .0500 ± .0020 0.8 Δ -- .1350 ± .0409 0.3 
HS578T .2888 ± .0564 4.4 .2441 ± .1003 3.5 1.9436 ± .5578 3.9 
231 .1602 ± .0172 2.4 .3387 ± .0956 4.8 1.4163 ± .2516 2.8 
MCF-10A .0663 ± .0188 1.0 .0707 ± .0130 1.0 .5022 ± .1556 1.0 
 
 
 
 
Figure 24.  Absolute protein levels of the MT isoforms in human breast cells.  Control 
(violet), ER+ (grey), and ER- (blue) human breast cells.  Protein data represents biological 
replicates where n=3.  Error bars indicate the standard deviation around the mean.  A 
two-way ANOVA followed with a Bonferroni posttest was run on all data sets.  
Significance was based on variation from control (MCF-10A).  Δ (no detection).  *P < .05.  
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0.065% of the total cytosolic proteins were MTs.  This correlates to a ~13-fold higher 
expression of total MTs in ER- compared to ER+ human breast cancer cell lines or a 3.9-
fold increase in MT expression in ER- cells compared to control or a 3.4-fold down-
regulation of MTs in ER+ cells compared to the control.  On an isoform basis, MT-2 was 
the dominant MT expressed throughout all the cell lines followed by MT-1E and MT-1X.   
There was approximately a 13-fold induction of MT-2 protein in the ER- cells compared 
to ER+ cells and a 3.6-fold induction of MT-1X.  MT-1E was not detected in the ER+ cell 
lines at the protein level (Figure 24, Table 11) or the transcript level (Figure 25, Table 
12). 
MT mRNA transcript levels in the human breast cells 
The general expression pattern of the MT isoforms at the transcript level was 
fairly consistent with the protein levels with some exceptions (Figure 25, Table 12).  The 
MT mRNA fold inductions were more pronounced for the MT-2 and MT-1X isoforms 
than was seen at the protein level.  There was ~100-fold induction of MT-2 mRNA from 
ER- cells compared to ER+ cells and ~44-fold induction of MT-1X.  There was also a ~394-
fold difference in MT mRNA isoform abundance between the MT-2 in the ER+ and MT-1X 
in the ER- cell lines (Figure 25, Table 12).  Noteworthy is the mRNA transcript level of 
MT-1E in the ER- and control cells which has comparable transcript levels to MT-2 but 
has only 17.3% the protein compared to MT-2.  The higher fold inductions seen at the 
mRNA compared to what was seen at the protein level could be an artifact of 
malignancy or another consideration may be that there is more Apo-MT in these cells 
which destabilizes the MTs and leaves them more susceptible to degradation. 
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Table 12.  Absolute quantitation values of MT mRNA transcripts in human breast                   
cells.  Δ (no detection).  Values are average MT transcripts/1000 18S ± S.D. and 
represent three biological replicates.  Fold changes were calculated by comparing levels 
of each MT isoform from each malignant cell line to that of the MT levels found in the 
control (MCF-10A). 
 
  Relative  Relative  Relative 
 MT-1X Change MT-1E Change MT-2A Change 
MCF-7 .0016 ± .0006 0.3 Δ -- .0058 ± .0030 0.3 
T-47D .0003 ± .0002 0.1 Δ -- .0012 ± .0009 0.1 
HS578T .0131 ± .0040 2.0 .0535 ± .0075 2.0 .1183 ± .0138 5.4 
231 .0044 ± .0009 0.7 .0513 ± .0338 1.9 .0670 ± .0170 3.0 
MCF-10A .0065 ± .0002 1.0 .0272 ± .0068 1.0 .0220 ± .0048 1.0 
 
 
 
 
Figure 25.  Absolute mRNA transcript levels of the MT isoforms in human breast cells.  
Control (violet), ER+ (grey), and ER- (blue) human breast cells.  Absolute mRNA 
transcripts were normalized to 18S.  mRNA data represents biological replicates where 
n=3.  Error bars indicate the standard deviation around the mean.  A two-way ANOVA 
followed with a Bonferroni posttest was run on all data sets.  Significance was based on 
variation from control (MCF-10A).  Δ (no detection).  *P < .05. 
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CHAPTER IV 
 
DISCUSSION 
 In this study we describe a bottom-up proteomic-based approach leading to the 
development, optimization, validation, and application of an alternative means to 
quantify the individual MT isoforms at the protein level.   While others have described 
top-down methods for identifying MTs using MS in induced lysates38, 55, to date, this is 
the most robust study of this type describing quantitation of the individual MT isoforms 
in acute metal exposure and also the application to malignant and non-malignant cells.  
Earlier studies describing levels of MTs in metal exposures or disease relied heavily on 
mRNA levels and/or the antibody-based immunohistochemistry technique using the E-9 
antibody to measure total MT levels of the proteins4, 86-90.  The result of this study 
provides a non-antibody-based method to quantify MT isoforms at the protein level 
rather than rely on traditional PCR-based methods used to quantify MTs that may or 
may not correlate to actual protein expression.   
 Since 1957 when MTs were first identified, there has been a lack in development 
of a robust assay to measure levels of the individual protein isoforms that have so often 
been implicated as diagnostic or prognostic markers of disease.  The lack of 
development of such an assay is mostly due to the chemical (reactive) and physical 
(small) characteristics of the individual MTs.  The high sequence homology (Table 1) is 
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the major reason antibody based methods used to quantify MT proteins have been 
hampered.   
The use of mass spectrometry to characterize this family of proteins poses its 
own difficulties that needed to be overcome to reproducibly identify and quantitate the 
various MTs.  These problems were addressed in this study, namely, optimizing sample 
preparation and LC gradients to enrich for the diagnostic acetylated N-terminal tryptic 
peptides.  The COFRADIC approach has been used by many to gain sampling depth for 
proteomic studies involving complex lysates45, 63 and optimized 2-dimensional LC-MS 
(methods) was employed to characterize the complex MT family in this study.  Another 
difficulty with using MS for MTs is that the intact MT proteins are quite small and the 
sequence is highly conserved for all of the isoforms so when digested with trypsin many 
of the peptides are the same but the diagnostic N-terminal tryptic peptides have small 
differences in the sequence and can be identified by the mass differences.  Methionine 
oxidation was also a very important issue that needed to be addressed in this study.  It’s 
been shown that certain peptides containing methionine demonstrate a high 
susceptibility to undergo methionine oxidation79 and the diagnostic N-terminal tryptic 
peptides of MTs would fall in this category being prone to undergo methionine 
oxidation according to their results.  It is likely that there is a certain level of 
endogenous methionine oxidation as it has been speculated that methionine oxidation 
is a modification that can affect the functions of the proteins91 or help protect the cell 
through MTs redox potential.  There is also a good chance that a certain level of this 
modification is seen arising from a sample preparation artifact (oxygen in atmosphere 
74 
 
and buffers).  Whether methionine oxidation results from endogenous sources, 
exogenous sources, or both, it was clear that this modification needed to be resolved to 
increase quantitation accuracy and assay sensitivity.  Since a large portion of the MTs in 
the samples had methionine oxidation, converting the remaining reduced methionines 
to the oxidized forms was tested using hydrogen peroxide or sodium periodate92, 93.  
Unfortunately, this complicated the samples more as methionine can undergo two 
oxidation states (mono- or di) and was not controllable.  Eventually reverting the 
oxidized methionines back to their reduced forms with DMS57, 80 was tested.  This 
successfully converted the diagnostic N-terminal peptides into one reduced form for 
each isoform, increasing quantitation accuracy and sensitivity.  The last main challenge 
to overcome for characterizing the various MT isoforms using MS was to develop a 
reliable labeling technique for quantitation.  There are various methods used for MS-
based quantitation including label-free and stable Isotope labeling methods, each 
having their own pros and cons94.  Label-free methods of quantitation are the most 
inexpensive methods but are hampered by complex data analysis, normalization to 
achieve accurate/consistent results, and the lack at obtaining absolute protein values.  
Stable isotope labeling is often the most precise MS-based quantitation method used to 
achieve relative or absolute protein abundances but the reagents or heavy-labeled 
peptide standards may become costly.  The use of light and heavy iodoacetamide 
(alkylating agent) was used in this study because the MT peptides of interest contained 
5 cysteine residues which allows for adequate separation of light and heavy isotopic 
envelopes and the heavy iodoacetamide was not cost-prohibitive.  Also, despite the 5 
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Da mass shift between the light and heavy peptides, they separated 
chromatographically identical thus allowing for precise protein quantitation. 
 There is an obvious need for an MS-based assay for MT proteins in the 
biomarker field since MTs have been studied extensively as markers of metal toxicity 
and disease, most notably cancers24-31.  MTs have a protective role against metals 
(mostly cadmium) in cells and tissues.  It is known that cadmium accumulates in the 
kidney and MTs act as a sponge to bind free cadmium and protect the kidney from this 
carcinogenic and nephrotoxic metal95.  It has not been entirely clear yet as to which 
isoforms are responsible for binding metals (zinc, cadmium, copper, etc) in the cell in 
acute vs. chronic or low-dose vs. high-dose exposures to these heavy metals.  Much of 
the data to date has been a reflection of the mRNA transcript levels coupled with total 
MT protein obtained using the E-9 antibody12, 29, 30, 31, 33.  The results obtained in the 
present study give a clearer insight as to what MTs (proteins and mRNA) are inducible or 
protective in acute cadmium exposure (cell culture data) and perhaps what MTs play a 
protective role during chronic cadmium exposure as seen from the tissue data.  
Although there were some similarities in expression of transcripts and proteins for the 
MTs, an important finding in this study was seen when these two bio-molecules were 
compared for the various isoforms.  There were differences in the rank order and fold 
inductions of the MTs.  This was not all that surprising since there are many variables 
from an mRNA transcript to a fully functional translated protein including: bio-molecule 
half-lives, metal stabilization of proteins, and translational efficiencies.  It does, 
however, bring in to question the accuracy of prior MT studies that have relied heavily 
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on mRNA levels of the various MTs to correlate to protein levels of those isoforms.  This 
finding further exemplifies the need for this type of assay to measure the individual 
proteins in metal exposures to fully understand the functional role of the isoforms.  
 As mentioned, MTs have been known to have altered expression in many 
different cancers and have been often correlated to patient prognosis.  It is not entirely 
clear as to the functional role MTs are playing in carcinogenesis, whether they are 
altered due to cellular stress or if they are actually involved in the development of 
cancers.  In certain neoplastic cells, MTs have shown to possess anti-apoptotic activity 
and can increase cancer cellular proliferation18, 96.  Either being up-regulated or down-
regulated in carcinogenesis, many of the studied MT isoforms seem to increase cancer 
progression.  MTs have also been shown to be responsible in resistance to 
chemotherapeutic agents by using their redox potential to inactivate free radicals that 
are metabolically formed due to the cancer drugs97.  Additionally, MTs have been 
implicated in the resistance to cisplatin by binding to the drug in cancers treated with 
this chemotherapeutic98.   
According to PCR-based methods of quantitation, there are studies that suggest 
MT-1G acts as a tumor suppressor gene in hepatocellular, breast, and thyroid cancer99, 
100, 101.  Recently, it has been suggested that increased levels of MT-1F and MT-2A are 
potential biomarkers of poor outcome of non-small cell lung cancer patients102.  In 
colorectal cancer, MT-1G, 1E, 1F, 1H, and 1M were shown to be significantly down-
regulated (assumed to be epigenetically regulated by hypermethylation) and correlate 
with worse prognosis37 and a separate study by this same group suggests that 
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correlating MT expression with p53 proteins enhances the prognostic power of each 
individual marker by predicting the progression of the disease103.  In glioma, it is 
postulated that MT-1E enhances the migration and invasion of glioma cells by inducing 
MMP-9 inactivation via upregulation of NF-kB p50104.  Other studies show 
overexpression of MT-1F and MT-2A in breast cancer is responsible for cell proliferation 
and in MCF-7 cells could be responsible for chemoresistance to doxorubicin31, 32, 105-107.  
An earlier study from our lab suggests that MT-1E may mediate cancer cell 
differentiation in breast cancer with relation to the estrogen receptor status of the 
cell29. 
The results from the breast cancer portion of this study demonstrated similar 
results in some aspects but also different from what has been proposed about the 
individual MT isoforms in these cancer cell lines based on PCR and antibody data.  There 
are significant differences in expression of the MT isoforms when comparing ER- to ER+ 
cell lines, not only at mRNA, but protein level as well.  An interesting finding was that 
the transcript levels of MT-2A and MT-1E were significantly overexpressed in ER- cells, 
but at the protein level, MT-2 was 6- to 8-fold more abundant than MT-1E.  Also 
notable, was the complete absence of expression for MT-1E at both the protein and 
mRNA levels in the ER+ breast cancer cells.   
The previous MT studies in breast cancer have relied heavily on PCR data and the 
transcript levels for MT-2A and MT-1E in the ER- cells was comparable to what has been 
published, suggesting that these two isoforms are highly expressed.  Some reports claim 
MT-1E was highly expressed at the transcript level in breast cancer cells and/or tissues30 
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while a larger study claims that MT-2A was the most abundant isoform31.  This current 
study demonstrates that MT-1E and MT-2A expressed comparable transcript levels with 
MT-2 displaying slightly higher (without significance) levels in this study which is in good 
agreement that these two isoforms are highly expressed in ER- breast cancers.  The most 
notable finding in this study, compared to what has been published in the past, is the 
fact that we are now able to identify which MTs at the protein level are responsible for 
the difference in expression previously seen with the antibody when comparing ER- to 
ER+ breast cancer cells.  In these cells, MT-2 is the isoform that is responsible for the 
major differences seen at the protein level when comparing ER- to ER+ cells.  From a 
biomarker standpoint, the power to detect and quantify the individual MT isoforms at 
the protein level increases the usefulness of this type of assay for biomarker detection 
and classifying tumors based on their MTs status may provide a good alternative to their 
traditional ER-status. 
Urine remains an attractive noninvasive biological fluid to screen for biomarkers 
of kidney and urologic diseases with MS.  Urinary protein analysis can be challenging but 
potentially can give helpful information regarding urinary tract diseases.  The difficulty 
in measuring urinary proteins lies in the variation of urine composition between 
individuals and sampling times.  Typical urine protein concentration varies considerably 
(1-10 mg/dl) and albumins are abundant, assuming ~50% yield for extracted protein 
from urine this corresponds to ~0.5-20 ml of normal urine.   The high salt content of 
urine is an additional challenge in MS-based urinary proteomics.  Once these challenges 
are overcome the result is a urinary protein library that may contain potential 
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biomarkers of disease once validated.  To date, several candidate biomarkers of bladder 
cancer have been identified through proteomic approaches108, 109.  Since MT-3 and other 
MTs are known to show altered expression in bladder and kidney cancer, it would be 
plausible that cancer cells could be shed into urine and MTs could be used as markers of 
disease.  The potential to detect MT-3 in the urine and/or to see if this protein was 
modified was also examined in this study.  Although human urine samples from 
volunteers were not analyzed in this study, reconstituted (freeze-dried) human urine 
was obtained and spiked with purified MT-3 protein.  It was found that organic 
precipitation of proteins in urine achieved the highest recovery of MT-3 and that there 
were no other modifications due to the fluid besides oxidation of methionine (which 
was expected).  The next step would be to apply this method to a larger study of 
diseased (bladder/kidney cancer) and healthy volunteers to look for significant changes 
in abundance of the individual MTs. 
Recently there have been more studies demonstrating the viability of using FFPE 
tissue specimens for shotgun proteomic analysis that could offer a retrospective 
biomarker discovery of certain diseases110-116.  The proteins in FFPE tissues have 
undergone extensive modifications due to the formaldehyde reaction with the amino 
groups of lysines and free protein N-termini.  Although these tissues have been fixed, 
labs have reported obtaining >90% recovery of FFPE tissue proteomes compared to 
those generated from frozen tissue117.  Most studies in this type of tissue use more of a 
global analysis of the FFPE proteome searching potential biomarkers of disease followed 
with validation steps but we aim to study targeted FFPE proteomics for MTs since we 
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already know MTs display altered expression in certain diseases.  Tissue from uterine 
sections was used in this study to attempt analyzing MT levels from these specimens.  
Using the E-9 antibody, the tissues stained positive for MTs in a single mono epithelial 
layer prior to MS attempts.  Multiple attempts to detect MTs using published FFPE 
protocols for protein extractions coupled to the optimized MS MT protocols failed to 
identify any isoforms in this family.  In retrospection, the amount of extracted protein 
from these samples was low which was the likely reason for no detections of MTs.  
Three 10 µm uterine tissue slices was the maximum amount used for protein extractions 
and using 10-15 X 10 µm would likely give a better likelihood of identifying MTs.  There 
were many (500-1000) protein (non-MT) identifications using these different extractions 
in the uterine tissue despite the low amount of protein analyzed.  However, recent 
experiments (performed by co-worker) in kidney FFPE tissue resulted in the positive 
identification of seven MT isoforms which were the identical seven isoforms identified 
and quantified in the frozen kidney tissue described in this study.  In these experiments 
10 X 10 µm kidney FFPE tissue slices were used with similar protein extraction methods 
and the same optimized MT MS protocols described in this study that was performed on 
the uterine FFPE tissue.  It is known from the quantitative MT analysis performed in the 
current study describing the frozen kidney tissue that MTs are abundant in this tissue 
which partly led to the successful identifications of the MTs in the kidney FFPE tissue.  It 
is not known exactly how abundant the MTs are in the uterine FFPE tissue, the MT 
antibody staining appeared weak so that more than likely was also a factor for not 
detecting any isoforms using MS analysis for that tissue.  Another important aspect that 
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led to the positive MT detections of the signature N-terminal peptides in kidney FFPE 
experiments was the increased starting tissue material (10 X 10 µM tissue slices).  These 
successful MT identifications in the kidney FFPE tissue leaves promise for using this type 
of tissue for retrospective MT studies in cancers but more work is still needed for 
reliable quantitative analysis. 
 This study describes an iodoacetamide stable isotope-labeling mass 
spectrometry-based method for simultaneous relative and absolute quantification of 
human metallothionein isoforms in complex cell or tissue lysates.  Additional research 
on the individual MTs in cases of metal exposure and disease are needed to shed light 
on the functional role these isoforms in disease.  This method expands the usefulness of 
human MT isoforms as potential biomarkers for specific diseases or environmental 
exposures to heavy metals.  
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APPENDIX A 
Abbreviations Used in Text 
Cd2+  cadmium chloride (CdCl2) 
mRNA  messenger ribonucleic acid 
RT-PCR  reverse transcription- polymerase chain reaction 
NMI-BC non-muscle invasive- bladder cancer 
NaCl  sodium chloride 
MeOH  methanol 
EtOH  ethanol  
COFRADIC combined fractional and diagonal chromatography  
BSA  bovine serum albumin 
SDS  sodium dodecyl sulfate 
PCR  polymerase chain reaction 
HCl  hydrochloride 
DTT  dithiothreitol 
IgG  immunoglobulin G 
BGG  bovine gamma globulin G 
BCA  bicinchoninic acid assay 
TBE  tris/borate/EDTA 
BCP  2-Bromo-1-chloropropane 
84 
 
UV  ultraviolet 
RNA  ribonucleic acid 
DNA  deoxyribonucleic acid 
DMEM  Dulbecco’s modified Eagle's medium 
CO2  carbon dioxide 
EDTA  ethylenediaminetetraacetic acid 
PBS  Phosphate buffered saline 
NIH  National Institute of Health 
AAALAC American Association for Accreditation of Laboratory Animal Care 
cDNA  complementary DNA 
PAGE  polyacrylamide gel electrophoresis 
TBS  tris buffered saline 
DAB  diaminobenzidine 
Ct  threshold cycle 
 
Units of Measure 
cm2  centimeters squared 
°C  degrees Celsius 
µM  micromolar (10-6 mole/liter) 
mL  milliliter (10-3 liter) 
µg  microgram (10-6 gram) 
sec  second 
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min  minute 
mM  millimolar (10-3 mole/liter) 
ga  gauge 
rpm  revolutions per minute 
hr  hour 
µm  micrometer (10-6 meter) 
No.  number 
mm  millimeter (10-3 meter) 
kDa  kiloDalton 
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APPENDIX B 
MSMS Spectra of Endogenous and Synthetic MT Peptides 
 
 
 
 
 
Supplemental Figure 1.  MT-1H (
15
N) MSMS for synthesized human peptide. 
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Supplemental Figure 2.  MT-1B (
15
N) MSMS for synthesized human peptide. 
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Supplemental Figure 3.  MT-1M (
15
N) MSMS for synthesized human peptide. 
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Supplemental Figure 4.  MT-1E (
15
N) MSMS for synthesized human peptide. 
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Supplemental Figure 5.  MT-1F (
15
N) MSMS for synthesized human peptide. 
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Supplemental Figure 6.  MT-1L (
15
N) MSMS for synthesized human peptide. 
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Supplemental Figure 7.  MT-3 (
15
N) MSMS for synthesized human peptide. 
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Supplemental Figure 8.  MT-1G2 (
15
N) MSMS for synthesized human peptide. 
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Supplemental Figure 9.  MT-1A (
15
N) MSMS for synthesized human peptide. 
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Supplemental Figure 10.  MT-1X (
15
N) MSMS for synthesized human peptide. 
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Supplemental Figure 11.  MT-2 (
15
N) MSMS for synthesized human peptide. 
 
 
 
97 
 
 
 
 
 
Supplemental Figure 13.  Endogenous MT-1E (
14
N) MSMS. 
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Supplemental Figure 14.  Endogenous MT-1M (
14
N) MSMS. 
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Supplemental Figure 15.  Endogenous MT-3 (
14
N) MSMS. 
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Supplemental Figure 16.  Endogenous MT-1G2 (
14
N) MSMS. 
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Supplemental Figure 17.  Endogenous MT-1X (
14
N) MSMS. 
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Supplemental Figure 18.  Endogenous MT-1F (
14
N) MSMS. 
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Supplemental Figure 19.  Endogenous MT-2 (
14
N) MSMS. 
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